Magnetar Financial LLC Acquires Shares of 12,023 USANA Health Sciences, Inc. $USNA

Key Points

• Magnetar Financial LLC acquired a new stake in USANA Health Sciences, purchasing 12,023 shares for approximately $324,000, representing about 0.06% of the company's stock.
• USANA reported quarterly earnings of $0.74 per share, exceeding analyst estimates of $0.54, with revenue of $235.85 million compared to expectations of $225.20 million.
• Insider trading activity showed a significant sale by David Mulham, who sold 3,515 shares at an average price of $30.26, indicating a 27.51% decrease in his holdings.

Magnetar Financial LLC bought a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 12,023 shares of the company's stock, valued at approximately $324,000. Magnetar Financial LLC owned about 0.06% of USANA Health Sciences at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of USANA Health Sciences by 35.4% during the fourth quarter. Wells Fargo & Company MN now owns 7,961 shares of the company's stock worth $286,000 after purchasing an additional 2,082 shares during the period. Barclays PLC increased its holdings in USANA Health Sciences by 12.0% in the fourth quarter. Barclays PLC now owns 31,067 shares of the company's stock valued at $1,116,000 after purchasing an additional 3,330 shares during the period. Dimensional Fund Advisors LP raised its position in USANA Health Sciences by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock worth $27,751,000 after purchasing an additional 55,059 shares during the last quarter. Hsbc Holdings PLC acquired a new position in USANA Health Sciences during the 4th quarter worth about $282,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of USANA Health Sciences by 15.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,234 shares of the company's stock valued at $260,000 after buying an additional 985 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded USANA Health Sciences from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, USANA Health Sciences currently has an average rating of "Hold" and a consensus target price of $36.00.

USANA Health Sciences Price Performance

Shares of USANA Health Sciences stock traded up $0.01 on Friday, hitting $31.78. 234,152 shares of the company's stock traded hands, compared to its average volume of 97,768. The company has a fifty day moving average of $31.24 and a two-hundred day moving average of $29.57. USANA Health Sciences, Inc. has a one year low of $23.10 and a one year high of $41.83. The company has a market capitalization of $580.58 million, a price-to-earnings ratio of 17.65, a price-to-earnings-growth ratio of 1.01 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.20. The firm had revenue of $235.85 million for the quarter, compared to analyst estimates of $225.20 million. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. Equities research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the transaction, the insider owned 9,260 shares of the company's stock, valued at $280,207.60. This represents a 27.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert A. Fuller sold 1,058 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $29.10, for a total value of $30,787.80. The disclosure for this sale can be found here. Insiders have sold a total of 5,073 shares of company stock worth $151,982 in the last quarter. 0.63% of the stock is owned by corporate insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.